Compare DHY & FOCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | DHY | FOCL |
|---|---|---|
| Founded | N/A | 1979 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 240.4M | 222.4M |
| IPO Year | 1998 | 1998 |
| Metric | DHY | FOCL |
|---|---|---|
| Price | $15.99 | $4.35 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $8.60 |
| AVG Volume (30 Days) | ★ 1.0M | 77.3K |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $70,527,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $34.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1.63 |
| 52 Week Low | $1.61 | $4.00 |
| 52 Week High | $16.67 | $6.40 |
| Indicator | DHY | FOCL |
|---|---|---|
| Relative Strength Index (RSI) | 99.08 | 50.30 |
| Support Level | $1.77 | $4.01 |
| Resistance Level | N/A | $4.50 |
| Average True Range (ATR) | 0.16 | 0.22 |
| MACD | 1.44 | 0.06 |
| Stochastic Oscillator | 95.35 | 62.58 |
Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.
Edap TMS SA, formerly known as FocalTherics, operates in the Robotic Focal Therapy industry. It develops, manufactures, and markets minimally invasive medical devices across various countries to treat various conditions using proprietary focused ultrasound technology. The company's flagship platform, Focal One Robotic HIFU, combines imaging, real-time treatment planning, robotic precision, and high intensity focused ultrasound (HIFU) technology. It is focused on expanding the clinical adoption of its patented focused ultrasound-based robotic therapy platforms through continued innovation, clinical evidence generation, physician education, and various market development initiatives.